Caris Life Sciences Launches New Blood Test for Early Cancer Detection
The test utilizes genomic sequencing and AI to identify biological signals associated with early-stage disease.
The test utilizes genomic sequencing and AI to identify biological signals associated with early-stage disease.
The new molecular panels are designed to detect up to 22 pathogens in one hour with enhanced norovirus detection.
The test detect signs of colorectal cancer and precancerous growths using a home collection kit.
The approval allows Quest Diagnostics to offer its minimal residual disease test for patients in all 50 states.
The point-of-care assay provides results in 15 minutes and received a waiver for use in decentralized settings.
A simplified test of HDL's ability to remove cholesterol was associated with high-risk coronary plaques in a study of 61 patients.
As autoimmune and allergy test volumes rise, labs are prioritizing workflow standardization and structured testing pathways to ensure reliable results, according to Santhosh Nair, president of immunodiagnostics at Thermo Fisher Scientific.
The assay measures enzyme activity in plasma to help clinicians identify acute ischemic stroke, which is often missed by standard imaging.
The study highlights the role of brain-derived nanoparticles in identifying the disease through minimally invasive testing.
Research suggests that only 12% of men receiving testosterone prescriptions underwent appropriate testing.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.